The research for immunological alteration in the pathogenesis of chronic inflammatory skin diseases including psoriasis, atopic dermatitis, SLE.

The research for immunological alteration in the pathogenesis of chronic inflammatory skin diseases including psoriasis, atopic dermatitis, SLE. - The immunological alteration in the chronic inflammatory skin diseases

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019215

Enrollment

100

Registered

2016-01-01

Start date

2013-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic inflammatory skin diseases including psoriasis, atopic dermatitis, SLE

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with psoriasis, atopic dermatitis, SLE

Exclusion criteria

Exclusion criteria: Patients with other inflammatory skin diseases

Design outcomes

Primary

Measure	Time frame
TNF blocker inhibitors down-regulate at least two distinct pathways to attenuate IL-17 signalling in psoriasis: a direct effect on Th17 cells and an indirect effect via other types of cells, such as TipDCs.	—

Secondary

Measure	Time frame
Anti-TNFa antibody didn't affect Th1 pathway.	—

Countries

Japan

Contacts

Public ContactKimiko Nakajima

Kochi Medical School, Kochi University Department of Dermatology

nakajimk@kochi-u.ac.jp088-880-2363

Outcome results